Causes of Color Blindness: Function and Failure of the Genes That Detect Color
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Vertebrate Retina Contains Two Types of Photoreceptors: Rods That
JOURNAL OF NEUROCHEMISTRY | 2009 | 108 | 91–101 doi: 10.1111/j.1471-4159.2008.05739.x *Department of Anatomy, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan Genetics and Development Division, Toronto Western Research Institute, University Health Network, Department of Ophthalmology and Visual Sciences and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada àUniversity of Ottawa Eye Institute and Ottawa Health Research Institute, Ottawa, Ontario, Canada Abstract The retinas of staggerer mice, carrying a null mutation of Color vision is supported by retinal cone photoreceptors that, RORa, show significant down-regulation of Opn1sw, in most mammals, express two photopigments sensitive to Opn1mw, and Arr3. RORa acts in synergy with cone-rod short (S-opsin) or middle (M-opsin) wavelengths. Expression homeobox transcription factor (Crx), to activate the Opn1sw of the Opn1sw and Opn1mw genes, encoding S-opsin and promoter in vitro. Chromatin immunoprecipitation assays re- M-opsin, respectively, is under the control of nuclear veal that RORa directly binds to the Opn1sw promoter, receptors, including thyroid hormone receptor b2 (TRb2), Opn1mw locus control region, and the Arr3 promoter in vivo. retinoid X receptor c (RXRc), and RORb, a member of the Our data suggest that RORa plays a crucial role in cone retinoic acid receptor-related orphan receptor (ROR) family. development by directly regulating multiple cone genes. We now demonstrate that RORa, another member of the ROR Keywords: arrestin, cone photoreceptor, opsin, retina, family, regulates Opn1sw, Opn1mw, as well as Arr3 (cone RORa, staggerer. arrestin) in the mouse retina. RORa expression is detected in J. -
Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials
RESEARCH ARTICLE Blue Cone Monochromacy: Visual Function and Efficacy Outcome Measures for Clinical Trials Xunda Luo1☯‡, Artur V. Cideciyan1☯‡*, Alessandro Iannaccone2, Alejandro J. Roman1, Lauren C. Ditta2, Barbara J. Jennings2, Svetlana A. Yatsenko3, Rebecca Sheplock1, Alexander Sumaroka1, Malgorzata Swider1, Sharon B. Schwartz1, Bernd Wissinger4, Susanne Kohl4, Samuel G. Jacobson1* 1 Scheie Eye Institute, Department of Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 2 Hamilton Eye Institute, Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States of America, 3 Pittsburgh Cytogenetics Laboratory, Center for Medical Genetics and Genomics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America, 4 Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Tuebingen, Germany ☯ These authors contributed equally to this work. ‡ OPEN ACCESS These authors are joint first authors on this work. * [email protected] (SGJ); [email protected] (AVC) Citation: Luo X, Cideciyan AV, Iannaccone A, Roman AJ, Ditta LC, Jennings BJ, et al. (2015) Blue Cone Monochromacy: Visual Function and Efficacy Abstract Outcome Measures for Clinical Trials. PLoS ONE 10(4): e0125700. doi:10.1371/journal.pone.0125700 Academic Editor: Dror Sharon, Hadassah-Hebrew University Medical Center, ISRAEL Background Blue Cone Monochromacy (BCM) is an X-linked retinopathy caused by mutations in the Received: December 29, 2014 OPN1LW / OPN1MW gene cluster, encoding long (L)- and middle (M)-wavelength sensitive Accepted: March 21, 2015 cone opsins. Recent evidence shows sufficient structural integrity of cone photoreceptors in Published: April 24, 2015 BCM to warrant consideration of a gene therapy approach to the disease. -
Color Blindness LEVELED BOOK • W a Reading A–Z Level W Leveled Book Word Count: 1,349 Color Blindness Connections Writing Choose Two Forms of Color Blindness
Color Blindness LEVELED BOOK • W A Reading A–Z Level W Leveled Book Word Count: 1,349 Color Blindness Connections Writing Choose two forms of color blindness. Write a report that compares the two conditions and their effects on a person’s life. Math Research the statistics about the number of people with the various forms of color blindness in your country. Organize your results in a pie chart. • W Q •T Written by Cheryl Reifsnyder Visit www.readinga-z.com for thousands of books and materials. www.readinga-z.com Words to Know Color ancestry molecules complementary photopigments cone cells prism Blindness defects retina genetic disorder rod cells hereditary wavelengths Photo Credits: Front cover, Back cover: © pretoperola/123RF; title page (Both): © shironosov/ iStock/Thinkstock; page 3: © Véronique Burger/Science Source; page 4 (Both): © Michael Shake/Dreamstime.com; page 5: © Designua/Dreamstime.com; page 6 (top): © Gunilla Elam/Science Source; page 6 (Bottom): © Steve Gschmeissner/Science Source; page 7 (Both): © Ted Kinsman/ Science Source; page 8 (left, Both): © anatchant/iStock/Thinkstock; page 8 (center, Both): © Nadezhda Bolotina/Hemera/Thinkstock; page 8 (right, Both): © iremphotography/iStock/Thinkstock; page 9 (all): © Popartic/iStock Editorial/Thinkstock; page 10: © RVN/Alamy Stock Photo; page 12: © Alexander Kaludov/123RF; page 13: © EnChroma; page 14: © Neitz LaBoratory; page 15: © Phanie/Alamy Stock Photo Written by Cheryl Reifsnyder www.readinga-z.com Focus Question Color Blindness Level W Leveled Book Correlation © Learning A–Z LEVEL W Written By Cheryl Reifsnyder What causes color blindness, and how Fountas & Pinnell S can it affect a person’s life? All rights reserved. -
RETINAL DISORDERS Eye63 (1)
RETINAL DISORDERS Eye63 (1) Retinal Disorders Last updated: May 9, 2019 CENTRAL RETINAL ARTERY OCCLUSION (CRAO) ............................................................................... 1 Pathophysiology & Ophthalmoscopy ............................................................................................... 1 Etiology ............................................................................................................................................ 2 Clinical Features ............................................................................................................................... 2 Diagnosis .......................................................................................................................................... 2 Treatment ......................................................................................................................................... 2 BRANCH RETINAL ARTERY OCCLUSION ................................................................................................ 3 CENTRAL RETINAL VEIN OCCLUSION (CRVO) ..................................................................................... 3 Pathophysiology & Etiology ............................................................................................................ 3 Clinical Features ............................................................................................................................... 3 Diagnosis ......................................................................................................................................... -
Investigating Cone Photoreceptor Development Using Patient-Derived NRL Null Retinal Organoids
ARTICLE https://doi.org/10.1038/s42003-020-0808-5 OPEN Investigating cone photoreceptor development using patient-derived NRL null retinal organoids Alyssa Kallman1,11, Elizabeth E. Capowski 2,11, Jie Wang 3, Aniruddha M. Kaushik4, Alex D. Jansen2, Kimberly L. Edwards2, Liben Chen4, Cynthia A. Berlinicke3, M. Joseph Phillips2,5, Eric A. Pierce6, Jiang Qian3, ✉ ✉ Tza-Huei Wang4,7, David M. Gamm2,5,8 & Donald J. Zack 1,3,9,10 1234567890():,; Photoreceptor loss is a leading cause of blindness, but mechanisms underlying photoreceptor degeneration are not well understood. Treatment strategies would benefit from improved understanding of gene-expression patterns directing photoreceptor development, as many genes are implicated in both development and degeneration. Neural retina leucine zipper (NRL) is critical for rod photoreceptor genesis and degeneration, with NRL mutations known to cause enhanced S-cone syndrome and retinitis pigmentosa. While murine Nrl loss has been characterized, studies of human NRL can identify important insights for human retinal development and disease. We utilized iPSC organoid models of retinal development to molecularly define developmental alterations in a human model of NRL loss. Consistent with the function of NRL in rod fate specification, human retinal organoids lacking NRL develop S- opsin dominant photoreceptor populations. We report generation of two distinct S-opsin expressing populations in NRL null retinal organoids and identify MEF2C as a candidate regulator of cone development. 1 Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, USA. 2 Waisman Center, University of Wisconsin-Madison, Madison, USA. 3 Department of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, USA. -
Genes in Eyecare Geneseyedoc 3 W.M
Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease. -
OCULAR GENE THERAPY TRIALS ADVANCE Results of the First Phase 3 Trial Were Announced
OCULAR GENE THERAPY TRIALS ADVANCE Results of the first phase 3 trial were announced. BY ARON SHAPIRO INNOVATIONS IN RETINA INNOVATIONS “We used to think that our fate was in our AAV FACILITATES GENE DELIVERY stars, but now we know that, in large measure, The nonpathogenic adeno-associated virus (AAV) has our fate is in our genes.” to date been a safe and effective vector for gene delivery. –James Watson1 The recombinant AAV (rAAV) vector has demonstrated increased specificity and efficiency in ocular AAV-mediated Genetic alterations are known to be respon- gene therapy interventions. Recombinant AAV2 (rAAV2) sible for numerous diseases, and so it follows vectors used for gene therapy are derived from the wild-type logically that the best cures for these diseases virus by deleting the entire viral coding region and replac- might lie in correcting genetic anomalies by the process of ing it with the reporter or therapeutic transgene. Combined gene therapy. This approach involves the introduction of AAV serotypes have also been developed. This diversity genes into existing cells in attempts to prevent or cure a of serotypes may lead to more specific and more efficient wide range of diseases previously thought to be incurable.1 transduction. However, successful and efficient transfection Posterior segment disorders are challenging to treat, and of particular cell types in the eye still depends on other fac- current therapies have numerous shortcomings. Many are tors, such as the AAV titer, the site of injection, the amount invasive, run the risk of complications, offer only short-term of passenger DNA, and the specific gene promoters where relief from symptoms, or are unable to directly treat vision transcription initiation takes place.2 loss. -
Updates on Myopia
Updates on Myopia A Clinical Perspective Marcus Ang Tien Y. Wong Editors Updates on Myopia Marcus Ang • Tien Y. Wong Editors Updates on Myopia A Clinical Perspective Editors Marcus Ang Tien Y. Wong Singapore National Eye Center Singapore National Eye Center Duke-NUS Medical School Duke-NUS Medical School National University of Singapore National University of Singapore Singapore Singapore This book is an open access publication. ISBN 978-981-13-8490-5 ISBN 978-981-13-8491-2 (eBook) https://doi.org/10.1007/978-981-13-8491-2 © The Editor(s) (if applicable) and The Author(s) 2020, corrected publication 2020 Open Access This book is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifc statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. -
Guthrie Cdna Resource Center
cDNA Resource Center cDNA Resource Center Catalog cDNA Resource Center Missouri University of Science and Technology 400 W 11th Rolla, MO 65409 TEL: (573) 341-7610 FAX: (573) 341-7609 EMAIL: [email protected] www.cdna.org September, 2008 1 cDNA Resource Center Visit our web site for product updates 2 cDNA Resource Center The cDNA Resource Center The cDNA Resource Center is a service provided by the faculty of the Department of Biological Sciences of Missouri University of Science and Technology. The purpose of the cDNA Resource Center is to further scientific investigation by providing cDNA clones of human proteins involved in signal transduction processes. This is achieved by providing high quality clones for important signaling proteins in a timely manner. By high quality, we mean that the clones are • Sequence verified • Propagated in a versatile vector useful in bacterial and mammalian systems • Free of extraneous 3' and 5' untranslated regions • Expression verified (in most cases) by coupled in vitro transcription/translation assays • Available in wild-type, epitope-tagged and common mutant forms (e.g., constitutively- active or dominant negative) By timely, we mean that the clones are • Usually shipped within a day from when you place your order. Clones can be ordered from our web pages, by FAX or by phone. Within the United States, clones are shipped by overnight courier (FedEx); international orders are shipped International Priority (FedEx). The clones are supplied for research purposes only. Details on use of the material are included on the Material Transfer Agreement (page 3). Clones are distributed by agreement in Invitrogen's pcDNA3.1+ vector. -
Colour Vision Deficiency
Eye (2010) 24, 747–755 & 2010 Macmillan Publishers Limited All rights reserved 0950-222X/10 $32.00 www.nature.com/eye Colour vision MP Simunovic REVIEW deficiency Abstract effective "treatment" of colour vision deficiency: whilst it has been suggested that tinted lenses Colour vision deficiency is one of the could offer a means of enabling those with commonest disorders of vision and can be colour vision deficiency to make spectral divided into congenital and acquired forms. discriminations that would normally elude Congenital colour vision deficiency affects as them, clinical trials of such lenses have been many as 8% of males and 0.5% of femalesFthe largely disappointing. Recent developments in difference in prevalence reflects the fact that molecular genetics have enabled us to not only the commonest forms of congenital colour understand more completely the genetic basis of vision deficiency are inherited in an X-linked colour vision deficiency, they have opened the recessive manner. Until relatively recently, our possibility of gene therapy. The application of understanding of the pathophysiological basis gene therapy to animal models of colour vision of colour vision deficiency largely rested on deficiency has shown dramatic results; behavioural data; however, modern molecular furthermore, it has provided interesting insights genetic techniques have helped to elucidate its into the plasticity of the visual system with mechanisms. respect to extracting information about the The current management of congenital spectral composition of the visual scene. colour vision deficiency lies chiefly in appropriate counselling (including career counselling). Although visual aids may Materials and methods be of benefit to those with colour vision deficiency when performing certain tasks, the This article was prepared by performing a evidence suggests that they do not enable primary search of Pubmed for articles on wearers to obtain normal colour ‘colo(u)r vision deficiency’ and ‘colo(u)r discrimination. -
Clinical and Genetic Investigation of a Large Tunisian Family with Complete Achromatopsia: Identification of a New Nonsense Mutation in GNAT2 Gene
Journal of Human Genetics (2011) 56, 22–28 & 2011 The Japan Society of Human Genetics All rights reserved 1434-5161/11 $32.00 www.nature.com/jhg ORIGINAL ARTICLE Clinical and genetic investigation of a large Tunisian family with complete achromatopsia: identification of a new nonsense mutation in GNAT2 gene Farah Ouechtati1,2,7, Ahlem Merdassi2,7, Yosra Bouyacoub1,2, Leila Largueche2, Kaouther Derouiche2, Houyem Ouragini1, Sonia Nouira1, Leila Tiab3,4, Karim Baklouti2, Ahmed Rebai5, Daniel F Schorderet3,4,6, Francis L Munier3,4,6, Leonidas Zografos4,6, Sonia Abdelhak1 and Leila El Matri2 Complete achromatopsia is a rare autosomal recessive disease associated with CNGA3, CNGB3, GNAT2 and PDE6C mutations. This retinal disorder is characterized by complete loss of color discrimination due to the absence or alteration of the cones function. The purpose of the present study was the clinical and the genetic characterization of achromatopsia in a large consanguineous Tunisian family. Ophthalmic evaluation included a full clinical examination, color vision testing and electroretinography. Linkage analysis using microsatellite markers flanking CNGA3, CNGB3, GNAT2 and PDE6C genes was performed. Mutations were screened by direct sequencing. A total of 12 individuals were diagnosed with congenital complete achromatopsia. They are members of six nuclear consanguineous families belonging to the same large consanguineous family. Linkage analysis revealed linkage to GNAT2. Mutational screening of GNAT2 revealed three intronic variations c.119À69G4C, c.161+66A4T and c.875À31G4C that co-segregated with a novel mutation p.R313X. An identical GNAT2 haplotype segregating with this mutation was identified, indicating a founder mutation. All patients were homozygous for the p.R313X mutation. -
Structure of Cone Photoreceptors
Progress in Retinal and Eye Research 28 (2009) 289–302 Contents lists available at ScienceDirect Progress in Retinal and Eye Research journal homepage: www.elsevier.com/locate/prer Structure of cone photoreceptors Debarshi Mustafi a, Andreas H. Engel a,b, Krzysztof Palczewski a,* a Department of Pharmacology, Case Western Reserve University, Cleveland, OH 44106-4965, USA b Center for Cellular Imaging and Nanoanalytics, M.E. Mu¨ller Institute, Biozentrum, WRO-1058, Mattenstrasse 26, CH 4058 Basel, Switzerland abstract Keywords: Although outnumbered more than 20:1 by rod photoreceptors, cone cells in the human retina mediate Cone photoreceptors daylight vision and are critical for visual acuity and color discrimination. A variety of human diseases are Rod photoreceptors characterized by a progressive loss of cone photoreceptors but the low abundance of cones and the Retinoids absence of a macula in non-primate mammalian retinas have made it difficult to investigate cones Retinoid cycle directly. Conventional rodents (laboratory mice and rats) are nocturnal rod-dominated species with few Chromophore Opsins cones in the retina, and studying other animals with cone-rich retinas presents various logistic and Retina technical difficulties. Originating in the early 1900s, past research has begun to provide insights into cone Vision ultrastructure but has yet to afford an overall perspective of cone cell organization. This review Rhodopsin summarizes our past progress and focuses on the recent introduction of special mammalian models Cone pigments (transgenic mice and diurnal rats rich in cones) that together with new investigative techniques such as Enhanced S-cone syndrome atomic force microscopy and cryo-electron tomography promise to reveal a more unified concept of cone Retinitis pigmentosa photoreceptor organization and its role in retinal diseases.